The National Hemophilia Foundation (NHF) received a $300,000 unrestricted grant from the pharmaceutical company Novo Nordisk in early February. Dr. Alan Kinniburgh, NHF CEO, received the grant on behalf of the organization at Novo’s US headquarters in Princeton, NJ. More than 200 Novo employees gathered for the check presentation by Martin Soeters, president of Novo Nordisk, and for Kinniburgh’s speech on the history of bleeding disorders.
“I would like to thank Novo Nordisk for its generous contribution,” said Dr. Kinniburgh. “These funds will be used to continue our education initiatives and National Empowerment program that are already making a positive impact both on a national and local level.”
The grant will help fund NHF’s First Step program for families with children newly diagnosed with a bleeding disorders, NYLI, and public policy’s National Empowerment Program, which helps chapters communicate to their members the latest access to care issues.
Novo Nordisk has international headquarters in Denmark.